Next Article in Journal
Chromatographic Detection of 8-Hydroxy-2′-Deoxyguanosine in Leukocytes of Asbestos Exposed Workers for Assessing Past and Recent Carcinogen Exposures
Next Article in Special Issue
Role of Body-Fluid Biomarkers in Alzheimer’s Disease Diagnosis
Previous Article in Journal
Grip Strength: A Useful Marker for Composite Hepatic Events in Patients with Chronic Liver Diseases
Previous Article in Special Issue
Pathogenic PSEN1 Glu184Gly Mutation in a Family from Thailand with Probable Autosomal Dominant Early Onset Alzheimer’s Disease
Article

Association of Plasma Oligomerized Beta Amyloid with Neurocognitive Battery Using Korean Version of Consortium to Establish a Registry for Alzheimer’s Disease in Health Screening Population

1
Department of Neurology, Nowon Eulji Medical Center, Eulji University, Seoul 01830, Korea
2
Research and Development, PeopleBio Inc., Seongnam 13487, Korea
3
Department of Laboratory Medicine, Seoul National University Hospital Healthcare System Gangnam Center, Seoul 06236, Korea
4
Department of Psychiatrics, Seoul National University Hospital Healthcare System Gangnam Center, Seoul 06236, Korea
5
Healthcare Research Institute, Seoul National University Hospital Healthcare System Gangnam Center, Seoul 06236, Korea
6
Department of Neurology, Seoul National University Hospital Healthcare System Gangnam Center, Seoul 06236, Korea
*
Author to whom correspondence should be addressed.
Diagnostics 2020, 10(4), 237; https://doi.org/10.3390/diagnostics10040237
Received: 25 March 2020 / Revised: 10 April 2020 / Accepted: 17 April 2020 / Published: 20 April 2020
(This article belongs to the Special Issue Alzheimer’s Disease Pathophysiology)
The increasing prevalence of Alzheimer’s disease (AD) has become a global phenomenon presenting serious social and health challenges. For detecting early molecular changes in the disease, several techniques to measure varied species of amyloid beta in the peripheral blood have been recently developed, but the efforts to associate them with cognitive assessments have yet to produce sufficient data. We prospectively collected participants from the consecutive population who visited our center for brain health screening. In total, 97 participants (F:M = 58:39) aged 69.4 ± 7.52 were assessed. Participants performed the Korean version of the Consortium to Establish a Registry for Alzheimer’s disease (CERAD-K), the clinical dementia rating (CDR), plasma oligomeric amyloid-β (OAβ) level tests, routine blood tests, ApoE genotype, and brain MRI. Among total population, 55.7% had a CDR of 0, and 40.2% had a CDR of 0.5. The results showed that word memory and word recall, and the total scores of the CERAD-K were negatively correlated with the plasma OAβ level. With a cut-off value of 0.78 ng/mL for the OAβ level and a −1.5 standard deviation of age/sex/education adjusted norms for the CERAD-K; naming, word memory, word recall, word recognition, and total score were significantly correlated with the OAβ level. No correlation between the OAβ level and mini-mental status examination was found. Our results demonstrate that the level of plasma OAβ was well correlated with the measure of cognitive function through the CERAD-K in the field data collected from consecutive populations. Studies on longitudinal comparisons with large cohorts will further validate the diagnostic value of plasma OAβ as a useful biomarker for screening AD and predicting progression. View Full-Text
Keywords: Alzheimer’s disease; blood biomarker; amyloid-β protein; oligomer; cognitive assessment; CERAD Alzheimer’s disease; blood biomarker; amyloid-β protein; oligomer; cognitive assessment; CERAD
Show Figures

Figure 1

MDPI and ACS Style

Lee, J.-J.; Choi, Y.; Chung, S.; Yoon, D.H.; Choi, S.H.; Kang, S.-M.; Seo, D.; Park, K.-I. Association of Plasma Oligomerized Beta Amyloid with Neurocognitive Battery Using Korean Version of Consortium to Establish a Registry for Alzheimer’s Disease in Health Screening Population. Diagnostics 2020, 10, 237. https://doi.org/10.3390/diagnostics10040237

AMA Style

Lee J-J, Choi Y, Chung S, Yoon DH, Choi SH, Kang S-M, Seo D, Park K-I. Association of Plasma Oligomerized Beta Amyloid with Neurocognitive Battery Using Korean Version of Consortium to Establish a Registry for Alzheimer’s Disease in Health Screening Population. Diagnostics. 2020; 10(4):237. https://doi.org/10.3390/diagnostics10040237

Chicago/Turabian Style

Lee, Jung-Ju, Youngki Choi, Soie Chung, Dae H. Yoon, Seung H. Choi, Sung-Min Kang, David Seo, and Kyung-Il Park. 2020. "Association of Plasma Oligomerized Beta Amyloid with Neurocognitive Battery Using Korean Version of Consortium to Establish a Registry for Alzheimer’s Disease in Health Screening Population" Diagnostics 10, no. 4: 237. https://doi.org/10.3390/diagnostics10040237

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop